Data on Breast Cancer Described by Researchers at University of Texas MD Anderson Cancer Center (Real-world Neoadjuvant and Adjuvant Trastuzumab-containing Regimen Patterns and Their Association With Survival Among Patients With Operable …): Oncology – Breast Cancer

2024 DEC 13 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Investigators publish new report on Oncology - Breast Cancer. According to news originating from Houston, Texas, by NewsRx correspondents, research stated, “Chemotherapy in combination with trastuzumab is the standard neoadjuvant and adjuvant therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). Assessing the regimens administered to patients with HER2-positive BC in the real world is lacking.”

Financial supporters for this research include Cancer Prevention & Research Institute of Texas, Division of Education & Training at the University of Texas MD Anderson Cancer Center.

Our news journalists obtained a quote from the research from the University of Texas MD Anderson Cancer Center, “We evaluated neoadjuvant and adjuvant regimen patterns among HER2-positive BC patients (2007 to 2021) identified in a health insurance claims database. Female BC patients >= 18 years who received chemotherapy, surgery, and trastuzumab were chosen from Optum’s de-identified Clinformatics ® Data Mart database. Summary statistics, Joinpoint models, Kaplan-Meier survival curves, and Cox regression models were used to analyze the data. We identified 6474 patients (median age 60 years), 71.7% were White, 10.9% were Black, 8.6% were Hispanic, 4.1% were Asian, and 4.7% had unknown race/ethnicity. About 33.8% received neoadjuvant therapy and neoadjuvant therapy use increased with an annual percent change of 10.24% (P < .001). The three most common regimens were adjuvant docetaxel, carboplatin, and trastuzumab (TCH; 29.0%); adjuvant paclitaxel and trastuzumab (17.7%); and neoadjuvant TCH with pertuzumab followed by adjuvant trastuzumab (17.7%). The 5-year overall survival (OS) was 96% (95% CI, 95-96%). Patients had an increased risk of death if they were >= 59 years at diagnosis, had a health maintenance organization or other insurance plan, had dual Medicare/Medicaid eligibility, had a mastectomy, did not receive 18 cycles of trastuzumab, or received regimens not recommended by the National Comprehensive Cancer Network. Treatment regimen patterns for HER2-positive BC evolved in correspondence with the U.S.”

According to the news editors, the research concluded: “Food and Drug Administration’s approval of new drugs for this cancer and National Comprehensive Cancer Network treatment guidelines.”

This research has been peer-reviewed.

For more information on this research see: Real-world Neoadjuvant and Adjuvant Trastuzumab-containing Regimen Patterns and Their Association With Survival Among Patients With Operable Her2-positive Breast Cancer From 2007 To 2021. Breast Cancer Research and Treatment, 2024. Breast Cancer Research and Treatment can be contacted at: Springer, One New York Plaza, Suite 4600, New York, Ny, United States. (Springer - www.springer.com; Breast Cancer Research and Treatment - http://www.springerlink.com/content/0167-6806/)

The news correspondents report that additional information may be obtained from Mariana Chavez-MacGregor, University of Texas MD Anderson Cancer Center, Dept Hlth Serv Res Unit 1362, 1515 Holcombe Blvd, Houston, TX 77030, United States. Additional authors for this research include Hui Zhao, Jaime J. Laureano, Xiudong Lei, Jiangong Niu, Sharon H. Giordano and Chan Shen.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s10549-024-07552-y. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)